Effects of Opioid Use Disorder in Pregnancy on Long-Term Maternal and Child Outcomes
妊娠期阿片类药物使用障碍对母婴长期结局的影响
基本信息
- 批准号:10430172
- 负责人:
- 金额:$ 45.91万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-09-15 至 2024-06-30
- 项目状态:已结题
- 来源:
- 关键词:2 year oldABCB1 geneAdverse effectsAffectAmericanBehaviorBrainBrain imagingBuprenorphineChildChildhoodClinicalCognitiveConsensusDRD2 geneDataDrug KineticsEconomic BurdenEnvironmental Risk FactorEpigenetic ProcessExposure toFetal DevelopmentFetusFunctional Magnetic Resonance ImagingFutureGenesGeneticGenetic RiskGenetic VariationGenotypeGoalsHigh PrevalenceHigh Risk WomanHospitalizationImageImaging DeviceInfantInfant CareInfant DevelopmentInjuryKnowledgeLength of StayLifeMagnetic Resonance ImagingModelingMorphineMothersNeonatalNeonatal Abstinence SyndromeNeurodevelopmental ProblemOpioidOpioid replacement therapyOralOutcomeOverdosePatternPharmacogeneticsPlacentaPostpartum DepressionPredictive FactorPredisposing FactorPregnancyPregnancy OutcomePregnant WomenProblem behaviorPsychological FactorsPsychosocial FactorPublic HealthRelapseResearchRestRiskRisk FactorsSeveritiesTreatment FactorTreatment outcomeVariantWorkadverse pregnancy outcomebasebuprenorphine treatmentcognitive functioncombinatorialcost efficientdesigneffective therapyfetalfetal opioid exposuregenetic signaturegenetic varianthigh riskillicit opioidimaging approachimaging biomarkerimprovedin uteroinfant outcomeinnovationinsightinter-individual variationlongitudinal designmaternal opioid usematernal outcomemedication-assisted treatmentmultidisciplinaryneonatal brainneonatal outcomeneonatal periodneurodevelopmentnovelopioid exposureopioid misuseopioid useopioid use disorderopioid use in pregnancyopioid withdrawalpersonalized interventionpredictive modelingprenatalprescription opioidprospectivepsychologicpsychosocialpublic health relevancerelapse riskresponserisk predictionsocioeconomicssocioenvironmental factortooltreatment responsetreatment strategy
项目摘要
Project Summary: In the US, 14-21% of pregnant women are exposed to opioids during pregnancy. This re-
flects a doubling of prescribed opioid use and opioid use disorder (OUD) in pregnancy in the past dec-
ade. Opioid relapse during pregnancy and after delivery is high due to post-partum depression and other psy-
chosocial factors. In parallel, neonatal abstinence syndrome (NAS) rates have increased more than 3 to 20 fold
since 2000. Every 25 minutes, a baby is born dependent to opioids in the US. Children exposed to opioids pre-
natally and in the neonatal period are at risk of opioid misuse later in life, and may develop cognitive, behavior-
al and neurodevelopmental problems. All these preventable public health crises confer a significant societal
and economic burden, with loss of productive life. Despite the high prevalence of exposure to opioids, little is
known about the factors predisposing to poor maternal outcomes, and neurodevelopmental outcomes in chil-
dren with maternal OUD. Further, the effect of in-utero opioid exposure on placental function, fetal maturation
and neonatal brain activity are unknown. Tackling maternal opioid misuse and NAS requires a comprehensive
understanding of multiple maternal-infant factors. There is a critical need for early and targeted identification of
pregnant women with OUD at risk for relapse and poor long term maternal and childhood outcomes. Our long-
term goals are to reduce future maternal OUD and relapse on opioid maintenance therapy, decrease severity
of NAS, personalize NAS treatment, and improve neurodevelopment in children with in-utero opioid exposure.
The objective of this proposal is to determine multi-factorial genetic, psychosocial predictors of opioid related
maternal and infant outcomes using rigorous prospective longitudinal design, innovative combinatorial phar-
macogenetic approach, fetal MRI and neonatal brain resting state functional MRI analysis. Our earlier work
showed that maternal/neonatal genetic variations and opioid-pharmacogenetics were associated with NAS se-
verity and adverse effects of opioids. Our preliminary data show that children treated for NAS had significantly
worse cognitive function at two years of life. Based on our previous results, we hypothesize that a combination
of maternal and infant genetic profile, maternal psychosocial factors, maternal opioid treatment response, fetal
and neonatal neurodevelopment and NAS treatment will affect maternal and childhood outcomes with prenatal
opioid exposure.The specific aims are to: 1) Identify high-risk genetic profiles and psychosocial factors in preg-
nant women with opioid use disorder, and predisposing to poor maternal opioid maintenance treatment out-
comes; 2) Determine maternal-infant genetic profiles and maternal opioid treatment factors predicting adverse
fetal development, severity of NAS, and neonatal brain function; and 3) Develop predictive models for maternal
opioid relapse, and poor long-term neuro-developmental outcomes in children with in-utero opioid exposure.
Critical new knowledge from this research will enable safe, effective treatment of maternal-infant opioid expo-
sure and neurodevelopmental outcomes by enabling proactive risk predictions and personalized interventions.
项目总结:在美国,14-21%的孕妇在怀孕期间接触过阿片类药物。这个重新
项目成果
期刊论文数量(5)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Resting state functional MRI in infants with prenatal opioid exposure-a pilot study.
- DOI:10.1007/s00234-020-02552-3
- 发表时间:2021-04
- 期刊:
- 影响因子:2.8
- 作者:
- 通讯作者:
Pilot study of fetal brain development and morphometry in prenatal opioid exposure and smoking on fetal MRI.
- DOI:10.1016/j.neurad.2020.12.004
- 发表时间:2022-01
- 期刊:
- 影响因子:0
- 作者:Radhakrishnan R;Brown BP;Haas DM;Zang Y;Sparks C;Sadhasivam S
- 通讯作者:Sadhasivam S
Thalamocortical functional connectivity in infants with prenatal opioid exposure correlates with severity of neonatal opioid withdrawal syndrome.
产前阿片类药物暴露婴儿的丘脑皮质功能连接与新生儿阿片类药物戒断综合征的严重程度相关。
- DOI:10.1007/s00234-022-02939-4
- 发表时间:2022
- 期刊:
- 影响因子:2.8
- 作者:Radhakrishnan,Rupa;Vishnubhotla,RamanaV;Guckien,Zoe;Zhao,Yi;Sokol,GregoryM;Haas,DavidM;Sadhasivam,Senthilkumar
- 通讯作者:Sadhasivam,Senthilkumar
Global Brain Functional Network Connectivity in Infants With Prenatal Opioid Exposure.
- DOI:10.3389/fped.2022.847037
- 发表时间:2022
- 期刊:
- 影响因子:2.6
- 作者:Radhakrishnan R;Vishnubhotla RV;Zhao Y;Yan J;He B;Steinhardt N;Haas DM;Sokol GM;Sadhasivam S
- 通讯作者:Sadhasivam S
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Senthilkumar Sadhasivam其他文献
Senthilkumar Sadhasivam的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Senthilkumar Sadhasivam', 18)}}的其他基金
Perioperative Precision Medicine: Translating Science to Clinical Practice to Improve Safety and Efficacy of Opioids in Neonates, Children and Nursing Mothers
围手术期精准医学:将科学转化为临床实践,提高阿片类药物对新生儿、儿童和哺乳期母亲的安全性和有效性
- 批准号:
10676237 - 财政年份:2022
- 资助金额:
$ 45.91万 - 项目类别:
Perioperative Precision Medicine: Translating Science to Clinical Practice to Improve Safety and Efficacy of Opioids in Neonates, Children and Nursing Mothers
围手术期精准医学:将科学转化为临床实践,提高阿片类药物对新生儿、儿童和哺乳期母亲的安全性和有效性
- 批准号:
10368457 - 财政年份:2022
- 资助金额:
$ 45.91万 - 项目类别:
Effects of Opioid Use Disorder in Pregnancy on Long-Term Maternal and Child Outcomes
妊娠期阿片类药物使用障碍对母婴长期结局的影响
- 批准号:
10499023 - 财政年份:2018
- 资助金额:
$ 45.91万 - 项目类别:
Bedside prediction of opioid-induced respiratory depression in children with pupillometry
通过瞳孔测量法预测阿片类药物引起的儿童呼吸抑制
- 批准号:
9754219 - 财政年份:2018
- 资助金额:
$ 45.91万 - 项目类别:
Pharmacogenetics of Oxycodone, Personalized Care and Persistent Surgical Pain
羟考酮的药物遗传学、个性化护理和持续性手术疼痛
- 批准号:
9767807 - 财政年份:2016
- 资助金额:
$ 45.91万 - 项目类别:
Pharmacogenetics of Oxycodone, Personalized Care and Persistent Surgical Pain
羟考酮的药物遗传学、个性化护理和持续性手术疼痛
- 批准号:
9185658 - 财政年份:2016
- 资助金额:
$ 45.91万 - 项目类别:
Pharmacogenetics of Oxycodone, Personalized Care and Persistent Surgical Pain
羟考酮的药物遗传学、个性化护理和持续性手术疼痛
- 批准号:
9543612 - 财政年份:2016
- 资助金额:
$ 45.91万 - 项目类别:
Pharmacogenetics of Oxycodone, Personalized Care and Persistent Surgical Pain
羟考酮的药物遗传学、个性化护理和持续性手术疼痛
- 批准号:
10006082 - 财政年份:2016
- 资助金额:
$ 45.91万 - 项目类别:
相似海外基金
Resistance to paclitaxel in triple negative breast cancer cells is associated with ABCB1 gene rearrangement
三阴性乳腺癌细胞对紫杉醇的耐药性与 ABCB1 基因重排有关
- 批准号:
315555 - 财政年份:2014
- 资助金额:
$ 45.91万 - 项目类别:














{{item.name}}会员




